Skip To Main Content
C. Akunna Otele on Muck Rack

C. Akunna Otele

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C. Akunna

Contact C. Akunna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study

|
By Naresh Bumma, Joshua Richter, Mina Awad, Timothy J Inocencio, Megan Seraphin, Tito Roccia, Glenn S. Kroog, Tanya M. Wildes, C. Akunna Otele
| Nature Verified
Abstract There is a paucity of data in frail patients with multiple myeloma (MM) receiving bispecific antibodies (bsAbs). In LINKER-MM1 (NCT03761108), linvoseltamab (human BCMA×CD3 bsAb) demonstrated high response rates and a generally manageable safety profile in relapsed/refractory (RR)MM.
Open in Who Shared Issue with article?
See all 1 articles